v3.24.1.1.u2
Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue $ 13,008 $ 12,674
Vaxcyte Agreements    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 647 675
Vaxcyte Agreements | Research and Development Services    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 647 504
Vaxcyte Agreements | Materials Supply    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue   171
Collaboration and License Agreements and Supply Agreements    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 13,008 12,674
Collaboration and License Agreements and Supply Agreements | Bristol-Myers Squibb Company ("BMS")    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue   3,166
Collaboration and License Agreements and Supply Agreements | Merck Sharp & Dohme Corporation ("Merck")    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 6 2,553
Collaboration and License Agreements and Supply Agreements | Astellas Pharma Inc. ("Astellas")    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 11,385 6,272
Collaboration and License Agreements and Supply Agreements | Tasly Biopharmaceuticals Co., Ltd. ("Tasly")    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 970  
Collaboration and License Agreements and Supply Agreements | Vaxcyte    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 647 675
Collaboration and License Agreements and Supply Agreements | Merck KGaA, Darmstadt, Germany (operating in the United States and Canada under the name ''EMD Serono'')    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue   8
2020 Merck Master Services Agreement    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 6 2,553
2020 Merck Master Services Agreement | Research and Development Services    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 6 125
2020 Merck Master Services Agreement | Materials Supply    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue   2,428
Astellas License and Collaboration Agreement    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 11,385 6,272
Astellas License and Collaboration Agreement | Ongoing Performance Related to Unsatisfied Performance Obligations    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 7,230 2,572
Astellas License and Collaboration Agreement | Research and Development Services    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 1,623 1,157
Astellas License and Collaboration Agreement | Financing Component on Unearned Revenue    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 2,160 $ 2,543
Astellas License and Collaboration Agreement | Materials Supply    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 372  
Tasly License Agreement    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 970  
Tasly License Agreement | Research and Development Services    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 33  
Tasly License Agreement | Materials Supply    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue $ 937